


Amendments to the Claims

Please cancel Claims 2, 6 and 7. Please amend Claim 1. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) ~~A~~ An injectable sustained release composition comprising a poly(lactide-co-glycolide) ~~biocompatible, biodegradable~~ polymer having incorporated therein a bisphosphonate compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein;

R₁ is independently, H, alkyl, aryl or heteroaryl;

X is H, -OR₁ or halogen;


R₂ is H, O, S, N-(CH₂)_n, branched alkylene, branched or straight alkenylene or alkynylene;

n is an integer from about 0 to about 18;

Y is H, R₁, halogen, alkyl, aryl, heteroaryl, amino, cyano or amido group; and wherein the composition is in the form of a microparticle.


2. (Cancelled)

3. (Original) The sustained release composition of Claim 1, wherein the bisphosphonate compound has the following structure:




or a pharmaceutically acceptable salt thereof.

4. (Original) The sustained release composition of Claim 1, wherein the bisphosphonate compound has the following structure:



or a pharmaceutically acceptable salt thereof.

5. (Original) The sustained release composition of Claim 1, wherein the bisphosphonate compound has the following structure:



or a pharmaceutically acceptable salt thereof.

6. (Canceled)
7. (Canceled)
8. The sustained release composition of Claim 1, wherein the bisphosphonate is present from about 0.5% (w/w) to about 20% (w/w) of the total weight of the composition.